Testing PARP inhibitors on your endometrial cancer cells
Part of Cancer, Women’s health & pregnancy clinical trials.
This study is testing whether a special kind of medicine called a PARP inhibitor can work against endometrial cancer cells grown in a lab from your tumor. The goal is to find out which patients might benefit from this treatment in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have endometrial cancer that has not spread beyond the uterus and you are planning to have surgery to remove it.
- Your tumor is a high-grade endometrioid type, or a non-endometrioid type (like serous or clear cell), or has a P53 mutation.
- You do not have any other active cancer that was found less than 6 months ago (except for a common skin cancer).
- You are not in a situation where you cannot make your own decisions (like being under guardianship).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study medicine called PF-08634404 when combined with standard chemotherapy for people with advanced or recurrent endometrial cancer that is MMR-proficient (meaning the DNA repair system is working normally). The goal is to see if adding this medicine helps shrink or control the cancer better than chemotherapy alone.
This trial tests a chemotherapy combination (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab, followed by maintenance pembrolizumab either alone or with a PARP inhibitor called nesuparib. It is for women with advanced or recurrent endometrial cancer that is MMR-proficient (a type where the cells have a normal ability to fix DNA).
This Phase 1/2 study tests targeted drug(s) for endometrial cancer that has come back or never fully went away after prior treatments. You may be eligible if your tumor can be tested for specific biomarkers and your health allows treatment safely.
This study looks at how well a surgical tool is used during standard surgery for early endometrial cancer, and whether it relates to test results from fluid taken in the abdomen. It may help surgeons improve how samples are collected and interpreted during routine care.
This study looks at combining genetic testing with surgical exams to better understand endometrial cancer. It may help doctors see which treatments could work best for you.
This study uses a tumor “biomarker” test to guide treatment in people with endometrial cancer (and sometimes epithelial ovarian cancer). It tests whether tailoring weekly chemotherapy (paclitaxel) based on biomarker levels can help patients, especially when the cancer has come back or is advanced.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.